Regen BioPharma focuses on creating immune checkpoint medicines.  An immune checkpoint is a mechanism by which certain cells of the immune system, typically T cells, are kept from being fully activated.  This type of restraint on the immune system is important in the normal functioning of the immune system.  However, it is now well-established that many cancers have an ability to trick immune cells into up-regulating their checkpoints and thus shut down the ability of these immune cells to kill the tumor.  Several drugs which target checkpoints, termed checkpoint inhibitors, are currently used as standard of care in certain cancers.  Regen has been focusing its research on a novel immune checkpoint called NR2F6.